Atheron Therapeutics

Atheron Therapeutics is a private Shanghai-based biotechnology company focused on oncology, autoimmune disease, and inflammatory disorders. Its pipeline spans small molecules, oral peptides, antibody-based programs, bispecific antibodies, molecular glues, degraders, and next-generation T-cell engager approaches. The company highlights an IND-stage small-molecule MRGPRX2 program for mast cell-mediated disease, along with multiple preclinical immunology and oncology assets including ITK inhibition, CCNE1 molecular glue, and a KAT6A degrader. Atheron also describes a biologics discovery platform called Antibody Integrated Mastery (AIM), built to support multifunctional therapeutics such as multispecific antibodies, fusion proteins, and antibody-conjugated modalities. Recent company communications emphasize preclinical presentations at AACR 2026 and an EAACI 2026 update for its MRGPRX2 program.